Journal
FRONTIERS IN IMMUNOLOGY
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2017.01961
Keywords
Lactococcus lactis; mucosal tolerance; immunotherapy; autoimmunity; type 1 diabetes
Categories
Funding
- European Community's Health Seventh Framework Programme [NAIMIT 241447]
- Fund for Scientific Research Flanders [FWO-Vlaanderen G.0554.13N]
- KU Leuven [GOA 2014/010]
- EFSD/Sanofi Innovative Approaches Programme
- Flemish Research Foundation [FWO-Vlaanderen 11Y6716N]
Ask authors/readers for more resources
Genetically modified Lactococcus lactis bacteria have been engineered as a tool to deliver bioactive proteins to mucosal tissues as a means to exert both local and systemic effects. They have an excellent safety profile, the result of years of human consumption in the food industry, as well as a lack of toxicity and immunogenicity. Also, containment strategies have been developed to promote further application as clinical protein-based therapeutics. Here, we review technological advancements made to enhanced the potential of L. lactis as live biofactories and discuss some examples of tolerogenic immunotherapies mediated by mucosal drug delivery via L. lactis. Additionally, we highlight their use to induce mucosal tolerance by targeted autoantigen delivery to the intestine as an approach to reverse autoimmune type 1 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available